Day One Biopharmaceuticals (NASDAQ:DAWN) executives highlighted accelerating commercial momentum for OJEMDA and outlined ...

Fintel reports that on March 9, 2026, Wedbush downgraded their outlook for Day One Biopharmaceuticals (NasdaqGS:DAWN) from ...

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric ...

As nonprofit-governed Servier continues to make gains with its IDH-mutant glioma med Voranigo, the drugmaker is wading deeper into the rare oncology arena with a new M&A play.  | Servier on Friday ...

Servier, an independent international pharmaceutical group, is acquiring Day One Biopharmaceuticals for $21.50 per share in ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

Day One Biopharmaceuticals stock remains a "Strong Buy." Learn more about its outlook, surging revenue, and ADC pipeline catalysts.

Management projected full-year 2025 net product revenues of $140 million to $150 million for OJEMDA, citing "strong and persistent demand, deepening prescriber adoption, and consistent payer coverage" ...

Day One Biopharmaceuticals (DAWN) stock jumps 66% after French pharmaceutical company Servier announces $2.5 billion all-cash acquisition agreement.

XTL Biopharmaceuticals And DOV Pharmaceutical In Deal Valued At More Than $130 Million For Pain Killer NEW YORK, January 16 -- XTL Biopharmaceuticals Ltd. announced today that, through a wholly-owned ...

The global biopharmaceuticals market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over ...

-- Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. -- Transaction represents ...